Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic...

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Hematologic malignancies encompass a range of cancers affecting blood, bone marrow, and lymph nodes.
• Biomarkers are crucial for diagnosing, staging, and monitoring treatment response in these diseases.
• Soluble receptors and adhesion molecules are increasingly recognized as potential diagnostic and prognostic indicators.

Purpose of the Study:

• To investigate the diagnostic and prognostic utility of plasma soluble interleukin-2 receptor (sIL-2R), soluble CD8 (sCD8), and soluble intercellular adhesion molecule 1 (sICAM-1) in various hematologic malignancies.
• To explore the cellular source of sIL-2R in specific leukemia subtypes.
• To correlate the levels of these biomarkers with disease stage, subtype, and clinical outcomes.

Main Methods:

• Enzyme-linked immunosorbent assays (ELISA) were employed to quantify plasma levels of sIL-2R, sCD8, and sICAM-1 in approximately 100 patients across multiple hematologic malignancies.
• Malignant cells from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) were cultured with and without TPA to assess IL-2R (CD25) expression via indirect immunofluorescence.
• Supernatants from these cell cultures were analyzed for sIL-2R levels using ELISA.

Main Results:

• Elevated sIL-2R levels were observed in active stages of hairy cell leukemia (HCL), acute myelomonocytic leukemia (AMMoL), AML, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), ALL subtypes, adult T-cell leukemia (ATL), and mycosis fungoides (MF).
• Reduced sIL-2R levels were noted in remission phases of HCL and MF, and in pre-T-ALL, suggesting a role in monitoring disease activity.
• Plasma sCD8 levels showed varied correlations with disease subtypes and stages, being low in HCL and MF, and elevated in AML, AMMoL, accelerated CLL, PLL, ALL subtypes, and ATL. sICAM-1 levels were elevated in all leukemias but showed no clear relation to CLL activity.

Conclusions:

• Plasma sIL-2R is a promising biomarker for assessing disease stage, subtype, and prognosis in several hematologic malignancies.
• The study suggests that malignant cells may be a significant source of sIL-2R in HCL, ALL, and AML, but potentially not in B-CLL.
• sCD8 may also serve as a marker for specific hematologic cancer subtypes and disease progression, while sICAM-1's role requires further investigation.